METHOD OF TREATMENT OF CHRONIC EROSIVE GASTRITIS ASSOCIATED WITH HELICOBACTER PYLORI AND EPSTEIN-BARR VIRUS Russian patent published in 2019 - IPC A61M5/32 A61K31/215 A61K31/29 A61K31/43 A61K31/4439 A61K31/7048 A61P1/04 A61P31/12 A61P37/02 A61B1/273 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gastroenterology, and can be used to treat chronic erosive gastritis associated with Helicobacter pylori (HP) and Epstein-Barr virus (EBV). Evaluate the results of determining the number of EBV copies in biopsy samples by the polymerase chain reaction method by 10⁵ infiltrate cells. At the same time, the number of copies of EBV in the gastric mucosa is determined by the treatment regimen for chronic erosive gastritis associated with HP and EBV. This includes conduct anti-helicobacter therapy, the duration of which depends on the contamination of the gastric mucosa HP. Furthermore, prophylactic courses of treatment are carried out to prevent the exacerbation of the disease by administering the drug cycloferon 12.5 % in a dose of 2.0 ml intramuscularly. In this case, if the number of copies of EBV in the gastric mucosa is 10,000 by 10⁵ and more infiltrate cells, the severity of chronic erosive gastritis is considered severe. In this case, against the background of anti-helicobacter therapy, cycloferon is administered simultaneously according to the scheme 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 days. Further, after 14 days, then after 6 and 12 months, repeated courses of administration of cycloferon are carried out according to the following scheme: 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28. If the number of copies of EBV in the gastric mucosa is from 1000 to 10,000 by 10⁵ cell infiltration – the severity of the disease is regarded as average. In this case, against the background of anti-helicobacter therapy, cycloferon is administered according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23, 26, 29 days. Further, after 14 days, then after 6 months, the course of administration of cycloferon is repeated according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23, 26, 29 days. When the number of copies of EBV in the gastric mucosa from 100 to 1,000 by 10⁵ infiltrate cells – diagnose mild severity of the disease. Treatment is carried out against the background of anti-helicobacter therapy by administering cycloferon according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23 day, then to maintain the effect of 1 injection after 5 days 5 times. When the number of copies of EBV in the gastric mucosa doesn't exceed 100 to 10⁵ infiltrate cells – the severity of chronic erosive gastritis is regarded as not requiring EBV treatment. In this case, cycloferon is administered according to the scheme 1, 2, 4, 6, 8, 11, 14, 17, 20, 23 day once.

EFFECT: method provides a reduction in the frequency of exacerbations of the disease, the achievement of long-term clinical and endoscopic remission of the disease due to the individualization of the choice of means and the timing of treatment for a particular patient.

1 cl, 2 tbl, 3 ex